BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol 2006;20:15-8. [PMID: 16785265 DOI: 10.1177/1359786806066040] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Popp J, Leucht S, Heres S, Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009;9:71-7. [PMID: 18332898 DOI: 10.1038/tpj.2008.5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
2 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 12.2] [Reference Citation Analysis]
3 Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010;11:1561-71. [PMID: 21121776 DOI: 10.2217/pgs.10.123] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
4 Peprah K, Zhu XY, Eyunni SV, Etukala JR, Setola V, Roth BL, Ablordeppey SY. Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol. Bioorg Med Chem 2012;20:1671-8. [PMID: 22336245 DOI: 10.1016/j.bmc.2012.01.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
5 Peprah K, Zhu XY, Eyunni SV, Setola V, Roth BL, Ablordeppey SY. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem 2012;20:1291-7. [PMID: 22245230 DOI: 10.1016/j.bmc.2011.12.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
6 Fan L, You Y, Fan Y, Shen C, Xue Y. Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia. Neuropsychiatr Dis Treat 2021;17:1289-97. [PMID: 33958870 DOI: 10.2147/NDT.S305200] [Reference Citation Analysis]
7 Pringsheim T, Kelly M, Urness D, Teehan M, Ismail Z, Gardner D. Physical Health and Drug Safety in Individuals with Schizophrenia. Can J Psychiatry 2017;62:673-83. [PMID: 28718324 DOI: 10.1177/0706743717719898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gardner DM, Murphy AL, Kutcher S, Beaulieu S, Carandang C, Labelle A, Lalonde P, Malla A, Milliken H, O'Donovan C, Schaffer A, Soni J, Taylor VH, Williams R. Evidence review and clinical guidance for the use of ziprasidone in Canada. Ann Gen Psychiatry 2013;12:1. [PMID: 23347694 DOI: 10.1186/1744-859X-12-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Kao AC, Burnet PWJ, Lennox BR. Can prebiotics assist in the management of cognition and weight gain in schizophrenia? Psychoneuroendocrinology 2018;95:179-85. [PMID: 29883788 DOI: 10.1016/j.psyneuen.2018.05.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Selent J, Bauer-Mehren A, López L, Loza MI, Sanz F, Pastor M. A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints. Mol Pharmacol 2010;77:149-58. [PMID: 19903829 DOI: 10.1124/mol.109.060103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
11 Tan W, Fan H, Yu PH. Induction of subcutaneous adipose proliferation by olanzapine in rodents. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1098-103. [PMID: 20541579 DOI: 10.1016/j.pnpbp.2010.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
12 Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, Hussain A, Malla AA. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat 2015;11:685-93. [PMID: 25792838 DOI: 10.2147/NDT.S80925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009;3:5-15. [PMID: 19083283 DOI: 10.1016/j.pcd.2008.10.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
14 Iordanidou M, Tavridou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V, Bougioukas G, Manolopoulos VG. The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians. Pharmacogenet Genomics 2008;18:153-9. [PMID: 18192901 DOI: 10.1097/FPC.0b013e3282f4ae93] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011;95:163-212. [PMID: 21878363 DOI: 10.1016/j.pneurobio.2011.08.004] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
16 Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009;26:959-69. [PMID: 19888560 DOI: 10.1007/s12325-009-0070-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
17 Dehelean L, Romosan AM, Manea MM, Papava I, Andor M, Romosan RS. THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE. Acta Endocrinol (Buchar) 2019;15:342-8. [PMID: 32010353 DOI: 10.4183/aeb.2019.342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011;25:1035-59. [PMID: 22133326 DOI: 10.2165/11596300-000000000-00000] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 10.0] [Reference Citation Analysis]
19 Cha DS, Mcintyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opinion on Pharmacotherapy 2011;13:1587-98. [DOI: 10.1517/14656566.2012.656590] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
20 Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia Research 2009;110:95-102. [DOI: 10.1016/j.schres.2009.02.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
21 Gregoor JG, Mulder H, Cohen D, van Megen HJ, Egberts TC, Heerdink ER, van der Weide J. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2010;30:702-5. [PMID: 21105285 DOI: 10.1097/jcp.0b013e3181fa05a2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Loging W, Harland L, Williams-Jones B. High-throughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov 2007;6:220-30. [PMID: 17330071 DOI: 10.1038/nrd2265] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
23 Kassem M, Haddad C, Daccache C, Hayek C, Hallit S, Kazour F. Factors associated with overweight and obesity in Lebanese male patients with schizophrenia. Perspect Psychiatr Care 2021;57:1347-55. [PMID: 33244768 DOI: 10.1111/ppc.12697] [Reference Citation Analysis]
24 Rege S. Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management. Aust N Z J Psychiatry 2008;42:369-81. [DOI: 10.1080/00048670801961123] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
25 Opgen-rhein C, Brandl EJ, Müller DJ, Neuhaus AH, Tiwari AK, Sander T, Dettling M. Association of HTR2C , but not LEP or INSIG2 , genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010;11:773-80. [DOI: 10.2217/pgs.10.50] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
26 Baptista T, Dávila A, El Fakih Y, Uzcátegui E, Rangel NN, Olivares Y, Galeazzi T, Vargas D, Peña R, Marquina D, Villarroel V, Teneud L, Beaulieu S. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia: . International Clinical Psychopharmacology 2007;22:205-11. [DOI: 10.1097/yic.0b013e328080ca44] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
27 Chen C, Chen W, Chen C, Moyzis R, He Q, Lei X, Li J, Wang Y, Liu B, Xiu D, Zhu B, Dong Q. Genetic variations in the serotoninergic system contribute to body-mass index in Chinese adolescents. PLoS One 2013;8:e58717. [PMID: 23554917 DOI: 10.1371/journal.pone.0058717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
28 Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol 2012;27:605-14. [PMID: 24446539 DOI: 10.1002/hup.2270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
29 Chen Y, Wang S, Xu X, Liu X, Yu M, Zhao S, Liu S, Qiu Y, Zhang T, Liu B, Zhang G. Synthesis and Biological Investigation of Coumarin Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics. J Med Chem 2013;56:4671-90. [DOI: 10.1021/jm400408r] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 9.6] [Reference Citation Analysis]
30 Kim JH, Lee JO, Lee SK, Jung JH, You GY, Park SH, Park M, Kim SD, Kim HS. Clozapine activates AMP-activated protein kinase (AMPK) in C2C12 myotube cells and stimulates glucose uptake. Life Sciences 2010;87:42-8. [DOI: 10.1016/j.lfs.2010.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
31 Tian Y, Liu D, Wang D, Wang J, Xu H, Dai Q, Andriescue EC, Wu HE, Xiu M, Chen D, Wang L, Chen Y, Yang R, Wu A, Wei CW, Zhang X. Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. Schizophr Res 2020;215:270-6. [PMID: 31653580 DOI: 10.1016/j.schres.2019.10.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
32 Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171-181. [PMID: 20404009 DOI: 10.1124/jpet.110.167346] [Cited by in Crossref: 247] [Cited by in F6Publishing: 227] [Article Influence: 20.6] [Reference Citation Analysis]
33 Lohoff FW, Ferraro TN. Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opinion on Pharmacotherapy 2010;11:423-39. [DOI: 10.1517/14656560903508762] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
34 Delacrétaz A, Lagares Santos P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenet Genomics 2017;27:464-72. [PMID: 28945215 DOI: 10.1097/FPC.0000000000000313] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, Ochoa D, Navares-Gómez M, Santos-Molina E, Pintos-Sánchez E, Abad-Santos F. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. Adv Ther 2021;38:1035-54. [PMID: 33278020 DOI: 10.1007/s12325-020-01566-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Greenberg WM, Citrome L. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clin Pharmacokinet 2017;56:493-503. [DOI: 10.1007/s40262-016-0465-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
37 Smith RC, Segman RH, Golcer-dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008;8:228-36. [DOI: 10.1038/sj.tpj.6500474] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
38 Jensen GL. Drug-induced hyperphagia: what can we learn from psychiatric medications? JPEN J Parenter Enteral Nutr 2008;32:578-81. [PMID: 18753398 DOI: 10.1177/0148607108321708] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
39 Xiamuxi H, Wang Z, Li J, Wang Y, Wu C, Yang F, Jiang X, Liu Y, Zhao Q, Chen W, Zhang J, Xie Y, Hu T, Xu M, Guo S, Akber Aisa H, He Y, Shen J. Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics. Bioorganic & Medicinal Chemistry 2017;25:4904-16. [DOI: 10.1016/j.bmc.2017.07.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
40 Chen Y, Lan Y, Cao X, Xu X, Zhang J, Yu M, Liu X, Liu B, Zhang G. Synthesis and evaluation of amide, sulfonamide and urea – benzisoxazole derivatives as potential atypical antipsychotics. Med Chem Commun 2015;6:831-8. [DOI: 10.1039/c4md00578c] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
41 Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF. Gender-dependent consequences of chronic olanzapine in the rat: Effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl). 2012;221:155-169. [PMID: 22234378 DOI: 10.1007/s00213-011-2555-2] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 17.1] [Reference Citation Analysis]
42 Suetani RJ, Siskind D, Reichhold H, Kisely S. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology 2017;234:2989-3008. [DOI: 10.1007/s00213-017-4728-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
43 Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder: . Clinical Drug Investigation 2011;31:455-82. [DOI: 10.2165/11589060-000000000-00000] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
44 Wilffert B, Swen J, Mulder H, Touw D, Maitland-van der Zee A, Deneer V; KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm 2011;33:3-9. [DOI: 10.1007/s11096-011-9485-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
45 De Deurwaerdère P, Bharatiya R, Chagraoui A, Di Giovanni G. Constitutive activity of 5-HT receptors: Factual analysis. Neuropharmacology 2020;168:107967. [DOI: 10.1016/j.neuropharm.2020.107967] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
46 Nichols CD. Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol 2009;2009:475108. [PMID: 20029624 DOI: 10.1155/2009/475108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
47 Srivastava V, Deshpande SN, Nimgaonkar VL, Lerer B, Thelma B. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008;9:1055-68. [DOI: 10.2217/14622416.9.8.1055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
48 Wallace TJ, Zai CC, Brandl EJ, Müller DJ. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmgenomics Pers Med 2011;4:83-93. [PMID: 23226055 DOI: 10.2147/PGPM.S11866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
49 Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol 2010;25:133-8. [PMID: 20196182 DOI: 10.1002/hup.1097] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
50 Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008;108:1614-41. [PMID: 18476671 DOI: 10.1021/cr078224o] [Cited by in Crossref: 538] [Cited by in F6Publishing: 465] [Article Influence: 38.4] [Reference Citation Analysis]
51 Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 2009;10:1511-26. [DOI: 10.2217/pgs.09.102] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
52 Mondelli V, Anacker C, Vernon AC, Cattaneo A, Natesan S, Modo M, Dazzan P, Kapur S, Pariante CM. Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Transl Psychiatry 2013;3:e208. [PMID: 23321805 DOI: 10.1038/tp.2012.138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
53 Rico-Gomis JM, Palazón-Bru A, Triano-García I, Mahecha-García LF, García-Monsalve A, Navarro-Ruiz A, Villagordo-Peñalver B, Jiménez-Abril J, Martínez-Hortelano A, Gil-Guillén VF. Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. PeerJ 2016;4:e2163. [PMID: 27441116 DOI: 10.7717/peerj.2163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
54 Smith T, Sharp S, Manzardo AM, Butler MG. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci 2015;16:4416-28. [PMID: 25710722 DOI: 10.3390/ijms16034416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
55 Brennan MD. Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 2014;15:869-84. [PMID: 24897292 DOI: 10.2217/pgs.14.50] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
56 Milano W, De Rosa M, Milano L, Capasso A. Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome. Open Neurol J 2013;7:23-31. [PMID: 23894259 DOI: 10.2174/1874205X01307010023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, Arends J, Mulder H. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J 2012;12:62-7. [DOI: 10.1038/tpj.2010.66] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
58 Huang XF, Weston-Green K, Yu Y. Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. Obes Rev 2018;19:396-405. [PMID: 29119689 DOI: 10.1111/obr.12638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
59 Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatr Dis Treat 2015;11:2143-52. [PMID: 26316760 DOI: 10.2147/NDT.S50961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
60 Dipasquale S, Pariante CM, Dazzan P, Aguglia E, Mcguire P, Mondelli V. The dietary pattern of patients with schizophrenia: A systematic review. Journal of Psychiatric Research 2013;47:197-207. [DOI: 10.1016/j.jpsychires.2012.10.005] [Cited by in Crossref: 186] [Cited by in F6Publishing: 165] [Article Influence: 20.7] [Reference Citation Analysis]
61 Chang S, Lu M. Metabolic and Cardiovascular Adverse Effects Associated with Treatment with Antipsychotic Drugs. Journal of Experimental & Clinical Medicine 2012;4:103-7. [DOI: 10.1016/j.jecm.2012.01.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
62 Wilffert B, Swen J, Mulder H, Touw D, Maitland-Van der Zee AH, Deneer V; KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm 2013;35:369-75. [PMID: 21049305 DOI: 10.1007/s11096-010-9446-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
63 Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009;66:1013-22. [PMID: 19640511 DOI: 10.1016/j.biopsych.2009.06.005] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
64 Tsai MC, Chang CM, Liu CY, Chang PY, Huang TL. Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. Int J Psychiatry Clin Pract. 2011;15:106-111. [PMID: 22121858 DOI: 10.3109/13651501.2010.550400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
65 von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A, Gaebel W. The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics (Sao Paulo) 2010;65:885-94. [PMID: 21049217 DOI: 10.1590/s1807-59322010000900012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
66 Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs 2010;24:193-206. [PMID: 20155995 DOI: 10.2165/11530130-000000000-00000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
67 Almandil NB, Lodhi RJ, Ren H, Besag FMC, Rossolatos D, Ohlsen R, Slomp C, Lapetina DL, Plazzotta G, Murray ML, Al-Sulaiman AA, Gringras P, Wong ICK, Aitchison KJ. Associations between the LEP -2548G/A Promoter and Baseline Weight and between LEPR Gln223Arg and Lys656Asn Variants and Change in BMI z Scores in Arab Children and Adolescents Treated with Risperidone. Mol Neuropsychiatry 2018;4:111-7. [PMID: 30397599 DOI: 10.1159/000490463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
68 Fernø J, Vik-mo AO, Jassim G, Håvik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mørk S, Berge RK, Jørgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009;203:73-84. [DOI: 10.1007/s00213-008-1370-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
69 Cao X, Chen Y, Zhang Y, Qiu Y, Yu M, Xu X, Liu X, Liu B, Zhang G. Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics. European Journal of Medicinal Chemistry 2016;124:713-28. [DOI: 10.1016/j.ejmech.2016.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
70 Bah J, Westberg L, Baghaei F, Henningsson S, Rosmond R, Melke J, Holm G, Eriksson E. Further exploration of the possible influence of polymorphisms in HTR2C and 5HTT on body weight. Metabolism 2010;59:1156-63. [PMID: 20092861 DOI: 10.1016/j.metabol.2009.11.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
71 Hill MJ, Reynolds GP. Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics 2011;12:727-34. [PMID: 21391883 DOI: 10.2217/pgs.11.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
72 Murphy AL, Gardner DM, Kisely S, Cooke C, Kutcher SP, Hughes J. Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain. ISRN Obes 2013;2013:390130. [PMID: 24533223 DOI: 10.1155/2013/390130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
73 Cataldi M, Citro V, Resnati C, Manco F, Tarantino G. New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. Adv Ther 2021;38:2094-113. [PMID: 33761100 DOI: 10.1007/s12325-021-01669-y] [Reference Citation Analysis]
74 Álamo C, López-muñoz F, García-garcía P. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert Review of Neurotherapeutics 2014;14:593-605. [DOI: 10.1586/14737175.2014.915741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
75 Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, Franke B, Egberts AC. HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia: A Replication Study. Journal of Clinical Psychopharmacology 2009;29:16-20. [DOI: 10.1097/jcp.0b013e3181934462] [Cited by in Crossref: 64] [Cited by in F6Publishing: 17] [Article Influence: 4.9] [Reference Citation Analysis]
76 Yang F, Jiang X, Li J, Wang Y, Liu Y, Bi M, Wu C, Zhao Q, Chen W, Yin J, Zhang J, Xie Y, Hu T, Xu M, Guo S, Wang Z, He Y, Shen J. Synthesis, structure–activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics. Bioorganic & Medicinal Chemistry Letters 2016;26:3141-7. [DOI: 10.1016/j.bmcl.2016.04.087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
77 Shad MU. Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside. Behav Sci (Basel) 2021;11:97. [PMID: 34209185 DOI: 10.3390/bs11070097] [Reference Citation Analysis]
78 Luckhoff H, Phahladira L, Scheffler F, Asmal L, du Plessis S, Chiliza B, Kilian S, Emsley R. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophrenia Research 2019;206:171-6. [DOI: 10.1016/j.schres.2018.11.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
79 de Silva PN. Closing the medical mortality gap in patients with major psychiatric conditions. Br J Hosp Med (Lond) 2018;79:444-8. [PMID: 30070942 DOI: 10.12968/hmed.2018.79.8.444] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Di Giovanni G, De Deurwaerdère P. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacol Ther 2016;157:125-62. [PMID: 26617215 DOI: 10.1016/j.pharmthera.2015.11.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 10.9] [Reference Citation Analysis]
81 Chukhin E, Terevnikov V, Takala P, Hakko H, Putkonen H, Räsänen P, Stenberg JH, Eronen M, Joffe G. Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism? Nord J Psychiatry 2016;70:190-4. [PMID: 26450657 DOI: 10.3109/08039488.2015.1074283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
82 Sleister HM, Valdovinos MG. Why Research On the Pharmacogenetics of Atypical Antipsychotic-Induced Weight Gain in Individuals With Intellectual Disabilities Is Warranted. Journal of Mental Health Research in Intellectual Disabilities 2011;4:65-78. [DOI: 10.1080/19315864.2011.555600] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs 2013;27:249-57. [PMID: 23533011 DOI: 10.1007/s40263-013-0054-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
84 Puangpetch A, Unaharassamee W, Jiratjintana N, Koomdee N, Sukasem C. Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs. J Pharm Pharmacol 2018;70:536-42. [PMID: 29441581 DOI: 10.1111/jphp.12892] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
85 Loebel A, Xu J, Hsu J, Cucchiaro J, Pikalov A. The development of lurasidone for bipolar depression. Ann N Y Acad Sci 2015;1358:95-104. [PMID: 26771990 DOI: 10.1111/nyas.12965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
86 Reynolds GP. Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine. Ther Adv Psychopharmacol 2011;1:197-204. [PMID: 23983947 DOI: 10.1177/2045125311430112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
87 Chen Y, Xu X, Liu X, Yu M, Liu BF, Zhang G. Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics. PLoS One 2012;7:e35186. [PMID: 22558126 DOI: 10.1371/journal.pone.0035186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
88 Tarleton EK, Kennedy AG, Daley C. Primer for nutritionists: Managing the side effects of antidepressants. Clin Nutr ESPEN 2016;15:126-33. [PMID: 28531777 DOI: 10.1016/j.clnesp.2016.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
89 Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci 2017;18:E2174. [PMID: 29057817 DOI: 10.3390/ijms18102174] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
90 Kemp AJ, Kazi SE, Megna JL, Leontieva LV. Synergistic Effects of Psychotropics Leading to Extraordinary Weight Gain. Cureus 2021;13:e17978. [PMID: 34660157 DOI: 10.7759/cureus.17978] [Reference Citation Analysis]
91 Soria-Chacartegui P, Villapalos-García G, Zubiaur P, Abad-Santos F, Koller D. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Front Pharmacol 2021;12:711940. [PMID: 34335273 DOI: 10.3389/fphar.2021.711940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Zhang Y, Ren H, Wang Q, Deng W, Yue W, Yan H, Tan L, Chen Q, Yang G, Lu T, Wang L, Zhang F, Yang J, Li K, Lv L, Tan Q, Zhang H, Ma X, Yang F, Li L, Wang C, Zhang D, Zhao L, Wang H, Li X, Guo W, Hu X, Tian Y, Ma X, Li T; Chinese Antipsychotics Pharmacogenomics Consortium. Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance. Sci China Life Sci 2019;62:535-43. [PMID: 30929193 DOI: 10.1007/s11427-018-9489-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Cai HL, Tan QY, Jiang P, Dang RL, Xue Y, Tang MM, Xu P, Deng Y, Li HD, Yao JK. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl Psychiatry 2015;5:e661. [PMID: 26485545 DOI: 10.1038/tp.2015.161] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
94 Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther 2010;125:169-79. [PMID: 19931306 DOI: 10.1016/j.pharmthera.2009.10.010] [Cited by in Crossref: 238] [Cited by in F6Publishing: 219] [Article Influence: 18.3] [Reference Citation Analysis]
95 Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J Clin Psychopharmacol 2013;33:11-7. [PMID: 23277265 DOI: 10.1097/JCP.0b013e31827d145a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 4.1] [Reference Citation Analysis]
96 Huang L, Zhang W, Zhang X, Yin L, Chen B, Song J. Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics. Bioorg Med Chem Lett 2015;25:5299-305. [PMID: 26483200 DOI: 10.1016/j.bmcl.2015.09.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
97 Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int J Psychiatry Clin Pract 2014;18:229-42. [PMID: 25152019 DOI: 10.3109/13651501.2014.957705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
98 Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;66:120-35. [DOI: 10.1016/j.pnpbp.2015.12.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
99 Griggs JL, Mathai ML, Sinnayah P. Caralluma fimbriata extract activity involves the 5-HT2c receptor in PWS Snord116 deletion mouse model. Brain Behav 2018;8:e01102. [PMID: 30353709 DOI: 10.1002/brb3.1102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
100 Klemettilä JP, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. Eur Psychiatry 2015;30:296-302. [PMID: 25284335 DOI: 10.1016/j.eurpsy.2014.08.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
101 Sušilová L, Češková E, Hampel D, Sušil A, Šimůnek J. Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors. International Journal of Psychiatry in Clinical Practice 2017;21:112-7. [DOI: 10.1080/13651501.2017.1291818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
102 Zhu XY, Etukala JR, Eyunni SV, Setola V, Roth BL, Ablordeppey SY. Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants. Eur J Med Chem 2012;53:124-32. [PMID: 22520153 DOI: 10.1016/j.ejmech.2012.03.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
103 Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) 2010;18:2295-300. [PMID: 20339369 DOI: 10.1038/oby.2010.51] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
104 Carro L, Raviña E, Domínguez E, Brea J, Loza MI, Masaguer CF. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif. Bioorganic & Medicinal Chemistry Letters 2009;19:6059-62. [DOI: 10.1016/j.bmcl.2009.09.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]